Status unknownNCT05658679Updated Dec 21, 2022

Radiomics in Pancreatic Cancer

An observational study in Pancreatic Cancer, sponsored by Ruijin Hospital. Status unknown. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-12-21.

Sponsored by Ruijin Hospital · Observational

The sponsor has not verified this record recently (last verified Dec 2022), so the status shown — last known as Active, not recruiting — may be out of date.

Study type: Observational
Model: Case-control
Time perspective: Retrospective
Enrollment: 2,000
Ages: 18 Years to 80 Years
Sex: All

Study summary

The images of patients with pancreatic cancer were collected and analyzed based on the methodes of radiomics

Conditions studied

Pancreatic Cancer

Browse trials for

Pancreatic Neoplasms 3,310

In context

Pancreatic Neoplasms

3,310 studies on the registry are indexed under Pancreatic Neoplasms; 910 are open to participants now.

This study's planned enrollment of 2,000 is above the median of 200 across 636 observational studies indexed under Pancreatic Neoplasms.

Browse Pancreatic Neoplasms studies →

Lead sponsor

Ruijin Hospital is the lead sponsor of 667 studies on the registry; 376 are open to participants now.

Browse Ruijin Hospital studies →

Counted across the registry records on this site, refreshed daily.

Who can participate

Ages eligible: 18 Years to 80 Years
Sexes eligible: All
Accepts healthy volunteers: Yes
Sampling method: Non-probability sample

Study population

All participants willing to receive abdominal imaging could be included in this study

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Gender unlimited, 18-80 years old;
Received abdominal imaging;
informed consent signed.

Exclusion criteria

Exclusion Criteria:

Pregnant / lactating women；
Contraindications of imaging examination。

Study design

Observational model: Case-control
Time perspective: Retrospective
Enrollment: 2,000 participants (estimated)
Patient registry: No

Groups and cohorts

patients with pancreatic cancer
Patients with pancreatic tumors diagnosed clinically or pathologically
Participants without pancreatic cancer
Participants who judged the pancreas to be completely healthy through medical examination

What researchers measure

Primary outcomes

5-year survival rate
Time frame: 1 week

Study locations

No study locations are listed for this record.

References and documents

Publications

Fu N, Fu W, Chen H, Chai W, Qian X, Wang W, Jiang Y, Shen B. A deep-learning radiomics-based lymph node metastasis predictive model for pancreatic cancer: a diagnostic study. Int J Surg. 2023 Aug 1;109(8):2196-2203. doi: 10.1097/JS9.0000000000000469. PubMed 37216230 ↗

Timeline

Tracking since Sep 25, 2026

ElapsedEstimatedEstimated, not yet reached

Started Jan 2016 (actual). Primary completion is estimated for Dec 2023, 95 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered: Dec 5, 2022
First posted: Dec 21, 2022
StartActual: Jan 2016
Primary completionEst.: Dec 2023
CompletionEst.: Dec 2024
Last update: Dec 21, 2022

What these dates mean

Start.: When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.: When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.: When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.: Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.

No changes since tracking began. The registry record was last updated on Dec 21, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗

Registry details

Key details

Study ID: NCT05658679
Lead sponsor: Ruijin Hospital
Responsible party: Weishen WANG (Principal Investigator, Ruijin Hospital) — Principal investigator
First posted: Dec 21, 2022
Start date: Jan 2016
Primary completion: Dec 2023 (estimated)
Completion: Dec 2024 (estimated)
Last update: Dec 21, 2022

Oversight

FDA-regulated drug: No
FDA-regulated device: No

View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Pancreatic Neoplasms →

Other studies from this sponsor

Ruijin Hospital →

Start the discussion